Mankind Pharma inks in-licensing pact with China’s Chongqing Chenan Biopharmaceutical on two insulin analogues

Mankind Pharma inks in-licensing pact with China’s Chongqing Chenan Biopharmaceutical on two insulin analogues

Mankind Pharma partners with Chongqing Chenan Biopharmaceutical to enhance diabetes care with two new insulin analogues in India.

Mankind Pharma Partners with Chongqing Chenan Biopharmaceutical to Distribute Insulin Degludec in India

Mankind Pharma has entered into a formal agreement with Chongqing Chenan Biopharmaceutical to introduce two insulin analogues to the Indian market. The partnership grants the Indian pharmaceutical company the rights to market and distribute Insulin Degludec and the Insulin Degludec plus Aspart combination within the country. This collaboration focuses on expanding the availability of these

Mankind Pharma inks agreement for two insulin analogues in India

Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, for the commercialisation of two insulin analogues, Insulin Degludec and Insulin Degludec + Aspart Combination, in India. The partnership marks a step in Mankind Pharma’s strategy to strengthen its presence in diabetes care and broaden its portfolio of injectable therapies. The addition of these products wil…